Sumitomo Mitsui Trust Group
TXG icon

Sumitomo Mitsui Trust Group’s 10x Genomics TXG Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161M Sell
4,194,627
-915,587
-18% -$24M 0.09% 208
2026
Q1 		$108M Sell
5,110,214
-381,975
-7% -$7.64M 0.07% 258
2025
Q4 		$89.6M Buy
5,492,189
+110,970
+2% +$1.68M 0.05% 316
2025
Q3 		$62.9M Sell
5,381,219
-636,744
-11% -$8.3M 0.04% 402
2025
Q2 		$69.7M Buy
6,017,963
+654,597
+12% +$5.97M 0.04% 370
2025
Q1 		$46.8M Sell
5,363,366
-350,118
-6% -$4.41M 0.03% 458
2024
Q4 		$82M Sell
5,713,484
-659,728
-10% -$10.4M 0.06% 327
2024
Q3 		$144M Buy
6,373,212
+230,145
+4% +$4.76M 0.1% 198
2024
Q2 		$119M Buy
6,143,067
+2,521,289
+70% +$66M 0.09% 218
2024
Q1 		$136M Buy
3,621,778
+1,338,248
+59% +$58.8M 0.09% 224
2023
Q4 		$128M Buy
2,283,530
+565,059
+33% +$24.6M 0.09% 222
2023
Q3 		$70.9M Sell
1,718,471
-47,163
-3% -$2.45M 0.06% 357
2023
Q2 		$98.6M Sell
1,765,634
-255,435
-13% -$13.8M 0.08% 280
2023
Q1 		$113M Sell
2,021,069
-156,919
-7% -$7.33M 0.08% 258
2022
Q4 		$79.4M Sell
2,177,988
-29,270
-1% -$957K 0.06% 358
2022
Q3 		$62.9M Buy
2,207,258
+793,419
+56% +$30.2M 0.05% 413
2022
Q2 		$64M Sell
1,413,839
-204,514
-13% -$10.6M 0.05% 418
2022
Q1 		$123M Buy
1,618,353
+184,168
+13% +$16.1M 0.08% 275
2021
Q4 		$214M Sell
1,434,185
-90,020
-6% -$13.8M 0.13% 175
2021
Q3 		$222M Sell
1,524,205
-215,169
-12% -$36.9M 0.14% 160
2021
Q2 		$341M Buy
1,739,374
+518,185
+42% +$93.8M 0.2% 114
2021
Q1 		$221M Buy
1,221,189
+904,239
+285% +$156M 0.14% 173
2020
Q4 		$44.9M Buy
316,950
+214,682
+210% +$31.2M 0.03% 569
2020
Q3 		$12.8M Sell
102,268
-105,915
-51% -$11.1M 0.01% 739
2020
Q2 		$18.6M Buy
+208,183
New +$16.2M 0.01% 688

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Sumitomo Mitsui Trust Group's TXG Position: Q2 2026 in Review

Sumitomo Mitsui Trust Group reduced its 10x Genomics (TXG) stake by 18% in Q2 2026, selling an estimated $24M and leaving 4,194,627 shares worth $161M. The position accounts for 0.09% of the portfolio, ranked #208.

Sumitomo Mitsui Trust Group first reported a position in TXG in Q2 2020 and has held it in 25 quarters since. The position peaked at $341M in Q2 2021. 391 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Sumitomo Mitsui Trust Group held 4,194,627 shares of 10x Genomics worth $161M as of Q2 2026.
  • Sumitomo Mitsui Trust Group sold 915,587 10x Genomics shares in Q2 2026, an estimated $24M.
  • 10x Genomics made up 0.09% of Sumitomo Mitsui Trust Group's portfolio in Q2 2026, its #208 holding.
  • Sumitomo Mitsui Trust Group first reported a position in 10x Genomics in Q2 2020 and has held it in 25 quarters since.
  • Sumitomo Mitsui Trust Group's 10x Genomics position peaked at $341M in Q2 2021.
  • 391 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2026, filed 30 Jul 2026.